6月11日 - ** Summit Therapeutics公司SMMT.O 股价周四盘前交易上涨4%，报13.57美元，此前该公司撤回了计划中的股权融资。
** 据美国证券交易委员会（SEC）文件显示，这家生物制药肿瘤学公司以市场状况为由，撤回了 (link) 拟议的股票发行计划
** SMMT股价周三收跌8.7%，报13.05美元；此前该公司于周二晚间启动 (link) 的5亿美元募资计划，用于资助其肺癌药物ivonescimab
** 截至周三，该公司股价年内累计下跌25%，较4月20日创下的2026年盘中高点29.23美元低55%
** 据伦敦证券交易所集团（LSEG）数据显示，18位分析师的平均评级为“买入”，目标价中位数为32美元
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.